Zobrazeno 1 - 10
of 15
pro vyhledávání: '"William Knebel"'
Publikováno v:
Clinical Pharmacology in Drug Development
The key pharmacokinetic/pharmacodynamic (PK/PD) efficacy index for β‐lactam antibiotics is the percentage of time that free drug concentrations exceed the minimum inhibitory concentration (MIC) of bacteria during each dosing interval (fT>MIC). Cef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890be20a6dfab07830883cf6c5d19591
https://doi.org/10.1002/cpdd.907
https://doi.org/10.1002/cpdd.907
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:5849-5857
Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with bactericidal activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). This study aimed to (i) evaluate cefta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::939237eaad7b5eacf24875ef9a1b14b9
https://doi.org/10.1128/aac.02755-15
https://doi.org/10.1128/aac.02755-15
Autor:
Todd Riccobene, Timothy J. Carrothers, Shampa Das, Tatiana Khariton, James Li, John S. Bradley, William Knebel, Alena Jandourek
Publikováno v:
The Journal of Clinical Pharmacology. 57:345-355
Ceftaroline, the active form of the prodrug ceftaroline fosamil, is approved for use in adults with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI) in the United States and for similar indi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c1fa5c73bc65864f7e845d5d8870e9d
https://doi.org/10.1002/jcph.809
https://doi.org/10.1002/jcph.809
Autor:
Frank Jen, Bimal Malhotra, Marc R. Gastonguay, Kuan Gandelman, Ahmed El-Tahtawy, William Knebel
Publikováno v:
The Journal of Clinical Pharmacology. 53:505-516
The population pharmacokinetics (PPK) of atorvastatin and its principal active metabolite, o-hydroxyatorvastatin, were described in 6-17 years old pediatric hypercholesterolemia patients with a 2-compartment model for both parent and metabolite. Info
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bdb66dbc152f28c226c6643f02b8f3a
https://doi.org/10.1002/jcph.66
https://doi.org/10.1002/jcph.66
Autor:
Philip Chaikin, Marc R. Gastonguay, Jeannine Fisher, Tatsuo Uchimura, William Knebel, N. Rao, Akihisa Mori
Publikováno v:
The Journal of Clinical Pharmacology. 51:40-52
This model-based analysis quantifies the population pharmacokinetics (PK) of orally administered istradefylline, a selective adenosine A(2A) receptor antagonist, in healthy subjects and patients with Parkinson's disease, including the estimation of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a42a184f0028addf16fe4ac585d06e
https://doi.org/10.1177/0091270010363809
https://doi.org/10.1177/0091270010363809
Publikováno v:
The Journal of Clinical Pharmacology. 48:837-848
This analysis quantifies the population pharmacokinetics of subcutaneous and intravenous epoetin delta, an epoetin produced in a human cell line, in pediatric patients with chronic kidney disease and estimates the effects of covariate factors on epoe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179a63abd7a2e852f5280703f5af22b5
https://doi.org/10.1177/0091270008318218
https://doi.org/10.1177/0091270008318218
Publikováno v:
Clinical pharmacokinetics. 54(8)
The population pharmacokinetics of guanfacine extended release were characterized in pediatric patients aged 6–17 years using NONMEM and evaluated by predictive check and bootstrap. Data were described using a one-compartment model. A covariate mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a53ec519b8002d6307d38aa32020c4d
https://pubmed.ncbi.nlm.nih.gov/25724291
https://pubmed.ncbi.nlm.nih.gov/25724291
Publikováno v:
The Journal of Clinical Pharmacology. 44:590-598
The objective of this analysis was to describe the pharmacokinetic characteristics of anidulafungin in patients with serious fungal disease based on pharmacokinetic data collected during four recently completed or ongoing Phase II/III clinical studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1bb98f0f9ae14d785293d1e4cfda710
https://doi.org/10.1177/0091270004265644
https://doi.org/10.1177/0091270004265644
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 42(1)
Guanfacine extended-release (GXR) is a selective α2A-adrenergic receptor agonist approved in the United States for once-daily administration for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents ages 6–17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e17f646a2e91e7f851e9401c6afa1b3b
https://pubmed.ncbi.nlm.nih.gov/25373474
https://pubmed.ncbi.nlm.nih.gov/25373474
Autor:
David M. Kornhauser, James W. Hainer, Jeffrey S. Barrett, William Knebel, Kristen Johansen, Tsushung A. Hua, Henry J. Pieniaszek, J.J. van Lier, James L. Gaskill, Per Sprogel
Publikováno v:
Thrombosis Research. 101:243-254
Tinzaparin, a sodium salt of a low-molecular-weight heparin (LMWH) produced via heparinase digestion, is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism in conjunction with warfarin for the prevention of DVT in patients un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91d1f8e9eee739f62d128af30289c3d
https://doi.org/10.1016/s0049-3848(00)00412-6
https://doi.org/10.1016/s0049-3848(00)00412-6